Spotlight Correspondence
Leukemia (2005) 19, 132–134. doi:10.1038/sj.leu.2403453 Published online 28 October 2004
Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib
R G Piazza1,2, V Magistroni1, M Gasser3, F Andreoni1, A Galietta1, L Scapozza3 and C Gambacorti-Passerini1,4
- 1Department of Experimental Oncology, National Cancer Institute, Milan, Italy
- 2University of Milano Bicocca, S Gerardo Hospital, Monza
- 3Department of Chemistry and Applied BioSciences at the Swiss Federal Institute of Technology, Zurich, Switzerland
- 4Department of Internal Medicine, Section of Hematology, University of Milano Bicocca, San Gerardo Hospital, Monza
Correspondence: Dr C Gambacorti-Passerini, Department of Experimental Oncology, National Cancer Institute, Via Venezian 1, Milan 20133, Italy. Fax: +39 2 2390 3237; E-mail: carlo.gambacorti@istitutotumori.mi.it
Received 24 November 2003; Accepted 4 June 2004; Published online 28 October 2004.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Penetrating insights into pore formation
Nature Structural Biology News and Views (01 Feb 1997)
Inhibitors of Bcr-abl. breaking new ground again
Nature Chemical Biology News and Views (01 Feb 2006)
